Echinomycin (NSC 526417) in advanced ovarian cancer. A phase II trial of the Gynecologic Oncology Group.

Abstract

Twenty-two patients with recurrent carcinoma of the ovary progressive after initial chemotherapy (21 with cisplatin-based treatment) were entered on a phase II trial utilizing Echinomycin at a dosage of 1,500 micrograms/m2 every 4 weeks. There were two complete responders and no partial responders (9% response, 95% confidence intervals for complete and partial responses of 1-29%). Major toxicity was modest and consisted mainly of nausea and vomiting. Echinomycin displays minimal activity as salvage therapy in women with advanced ovarian cancer at this dose and schedule.

• Authors: H B Muss, J A Blessing, V V Baker, D R Barnhill, M D Adelson
• Journal: American journal of clinical oncology (Am J Clin Oncol) Vol. 13 Issue 4 Pg. 299-301 (Aug 1990) ISSN: 0277-3732 [Print] United States
• PMID: 2198794 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Quinoxalines
• Echinomycin

Topics

• Adult
• Aged
• Carcinoma (drug therapy)
• Drug Evaluation
• Echinomycin (administration & dosage, therapeutic use, toxicity)
• Female
• Humans
• Infusions, Intravenous
• Middle Aged
• Multicenter Studies as Topic
• Neoplasm Recurrence, Local
• Ovarian Neoplasms (drug therapy)
• Quinoxalines (therapeutic use)
• Remission Induction